Impact of Neoadjuvant Approach and Tumor Response on Survival in Pancreatic Adenocarcinoma

Abstract

Neoadjuvant therapy for pancreatic adenocarcinoma (PDAC) has evolved from single‐agent to multi‐agent approaches, largely informed by metastatic disease studies demonstrating improved survival; albeit at the price of increased toxicity. It remains unclear how response to varied neoadjuvant regimens impact survival. We hypothesized that tumor response to different neoadjuvant approaches reflects underlying tumor biology, and achieving a pathologic complete response (pCR) with single‐agent neoadjuvant may signal favorable biology.